Bayer, Regeneron begin PhIII trials for Eylea in China for wet AMD
This article was originally published in Scrip
Executive Summary
Following quickly on a US FDA approval of Regeneron Pharmaceuticals’ Eylea (aflibercept injection) for treating patients with neovascular (wet) age-related macular degeneration (AMD), Regeneron has announced that, in conjunction with its partner Bayer Healthcare, it has initiated a Phase III trial of Eylea in China.